Literature DB >> 3745699

Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy.

B J Maron, J K Wolfson, S E Epstein, W C Roberts.   

Abstract

Many patients with hypertrophic cardiomyopathy have signs and symptoms of myocardial ischemia and dysfunction. Although hypertrophy and increased left ventricular pressure can account for such abnormalities, altered small intramural coronary arteries have also been described in such patients. To determine the prevalence and extent as well as the clinical relevance of abnormal intramural coronary arteries, a histologic analysis of left ventricular myocardium obtained at necropsy was performed in 48 patients with hypertrophic cardiomyopathy (but without atherosclerosis of the extramural coronary arteries) and in 68 control patients with either a normal heart or acquired heart disease. In hypertrophic cardiomyopathy, abnormal intramural coronary arteries were characterized by thickening of the vessel wall and a decrease in luminal size. The wall thickening was due to proliferation of medial or intimal components, or both, particularly smooth muscle cells and collagen. Of the 48 patients with hypertrophic cardiomyopathy, 40 (83%) had abnormalities of intramural coronary arteries located in the ventricular septum (33 patients), anterior left ventricular free wall (20 patients) or posterior free wall (9 patients); an average of 3.0 +/- 0.7 abnormal arteries were identified per tissue section. Altered intramural coronary arteries were also significantly more common in tissue sections having considerable myocardial fibrosis (31 [74%] of 42) than in those with no or mild fibrosis (31 [30%] of 102; p less than 0.001). Abnormal intramural coronary arteries were also identified in three of eight infants who died of hypertrophic cardiomyopathy before 1 year of age. In contrast, only rare altered intramural coronary arteries were identified in 6 (9%) of the 68 control patients (0.1 +/- 0.05 abnormal arteries per section; p less than 0.001) and those arteries showed only mild thickening of the wall and minimal luminal narrowing. Moreover, of those patients with abnormal intramural coronary arteries, such vessels were about 20 times more frequent in patients with hypertrophic cardiomyopathy (0.9 +/- 0.2/cm2 myocardium) than in control patients (0.04 +/- 0.02/cm2 myocardium). Hence, abnormal intramural coronary arteries with markedly thickened walls and narrowed lumens are present in increased numbers in most patients with hypertrophic cardiomyopathy studied at necropsy and may represent a congenital component of the underlying cardiomyopathic process.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1986        PMID: 3745699     DOI: 10.1016/s0735-1097(86)80181-4

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  111 in total

Review 1.  Myocardial perfusion and coronary microcirculation: from pathophysiology to clinical application.

Authors:  Antonio L'Abbate; Gianmario Sambuceti; Danilo Neglia
Journal:  J Nucl Cardiol       Date:  2002 May-Jun       Impact factor: 5.952

2.  Transthoracic Doppler echocardiographic analysis of phasic coronary blood flow velocity in hypertrophic cardiomyopathy.

Authors:  J J Crowley; P S Dardas; A A Harcombe; L M Shapiro
Journal:  Heart       Date:  1997-06       Impact factor: 5.994

Review 3.  Nuclear cardiac imaging in hypertrophic cardiomyopathy.

Authors:  Jamshid Shirani; Vasken Dilsizian
Journal:  J Nucl Cardiol       Date:  2011-02       Impact factor: 5.952

Review 4.  The genetic basis of hypertrophic cardiomyopathy in cats and humans.

Authors:  Mark D Kittleson; Kathryn M Meurs; Samantha P Harris
Journal:  J Vet Cardiol       Date:  2015-12       Impact factor: 1.701

5.  Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction.

Authors:  M Fassbach; B Schwartzkopff
Journal:  Z Kardiol       Date:  2005-05

Review 6.  An approach to endomyocardial biopsy interpretation.

Authors:  K S Cunningham; J P Veinot; J Butany
Journal:  J Clin Pathol       Date:  2006-02       Impact factor: 3.411

7.  Endogenous endothelin 1 mediates angiotensin II-induced hypertrophy in electrically paced cardiac myocytes through EGFR transactivation, reactive oxygen species and NHE-1.

Authors:  María V Correa; Mariela B Nolly; Claudia I Caldiz; Gladys E Chiappe de Cingolani; Horacio E Cingolani; Irene L Ennis
Journal:  Pflugers Arch       Date:  2013-12-11       Impact factor: 3.657

Review 8.  Potential mechanisms of improvement after various treatments for hypertrophic obstructive cardiomyopathy.

Authors:  R D Leachman
Journal:  Tex Heart Inst J       Date:  1995

9.  Prognosis of hypertrophic cardiomyopathy: assessment by 123I-BMIPP (beta-methyl-p-(123I)iodophenyl pentadecanoic acid) myocardial single photon emission computed tomography.

Authors:  T Nishimura; S Nagata; T Uehara; T Morozumi; Y Ishida; T Nakata; O Iimura; C Kurata; Y Wakabayashi; H Sugihara; K Otsuki; T Wada; Y Koga
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

Review 10.  Athlete's heart or hypertrophic cardiomyopathy?

Authors:  Jörg Lauschke; Bernhard Maisch
Journal:  Clin Res Cardiol       Date:  2008-10-13       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.